Madison Avenue Partners, LP 13D/13G Filings for Keros Therapeutics, Inc. (KROS)

Madison Avenue Partners, LP 13D and 13G filings for Keros Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2025-05-14
5:49 pm
Purchase
2025-05-07 13G Keros Therapeutics, Inc.
KROS
Madison Avenue Partners, LP 2,614,402
6.400%
2,614,402increase
(New Position)
Filing